New evidence-based therapies have emerged over the past year, shaping updates in pharmacologic management across multiple conditions. This presentation will review recently approved and emerging medications, including cardiovascular agents such as aficamten for symptomatic hypertrophic cardiomyopathy and etripamil for paroxysmal supraventricular tachycardia.
Advances in the management of hereditary angioedema will also be highlighted, including novel therapies for both prophylaxis and acute treatment (e.g., garadacimab, donidalorsen, and sebetralstat). Additional agents (such as suzetrigine for pain) will additionally be considered.
Sample